# Neoadjuvant Radiotherapy Combined With Toripalimab for Locally Advanced Head and Neck Squamous Cell Carcinoma

> **NCT05861557** · PHASE2 · UNKNOWN · sponsor: **Tianjin Medical University General Hospital** · enrollment: 23 (estimated)

## Conditions studied

- Locally Advanced Head and Neck Squamous Cell Carcinoma

## Interventions

- **DRUG:** Toripalimab
- **RADIATION:** Stereotactic Body Radiation Therapy (SBRT)

## Key facts

- **NCT ID:** NCT05861557
- **Lead sponsor:** Tianjin Medical University General Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2023-05-20
- **Primary completion:** 2024-05-20
- **Final completion:** 2025-05-20
- **Target enrollment:** 23 (ESTIMATED)
- **Last updated:** 2023-05-17

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05861557

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05861557, "Neoadjuvant Radiotherapy Combined With Toripalimab for Locally Advanced Head and Neck Squamous Cell Carcinoma". Retrieved via AI Analytics 2026-06-05 from https://api.ai-analytics.org/clinical/NCT05861557. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*